- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00723177
Phase IIa Study of AV411, a Glial Activation Inhibitor, for Opioid Withdrawal (AV411)
October 11, 2016 updated by: New York State Psychiatric Institute
The Safety, Tolerability and Preliminary Efficacy of AV411, a Glial Activation Inhibitor, in Heroin Abusers Under Conditions of Morphine Maintenance and Withdrawal
Repeated use and/or abuse of opioid medications is generally associated with a characteristic withdrawal syndrome that develops after cessation of drug administration.
The present study is designed to evaluate the effectiveness of AV411 to alter opioid-induced withdrawal symptoms.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Opioid-induced cytokine release and glial activation has been proposed to directly contribute to the affective and physiological aspects of withdrawal.
Furthermore, cytokine release following opioid administration has been hypothesized to be a limiting factor in both the duration and magnitude of opioid-induced analgesia.
The two primary goals of our study are to assess AV411's ability to 1) reduce the opioid-withdrawal syndrome and 2) increase and prolong the analgesic effects of the mu-opioid agonist, oxycodone.
To explore whether AV411 decreases opioid-induced glial cell activation, some participants assigned to the placebo and high dose AV411 groups (n = 6 for each dose condition) will be studied twice with [11C]PK11195, a positron emission tomography (PET) radiotracer used to measure the peripheral benzodiazepine receptor (PBR) in the human brain.
The PBR is a receptor located on the mitochondria of the microglia and can be used to examine microglial activation in various brain regions.
Study Type
Interventional
Enrollment (Actual)
30
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
New York
-
New York, New York, United States, 10032
- New York State Psychiatric Institute/Columbia University
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
21 years to 45 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Adults between the ages of 21 and 45
- Current dependence on heroin according to (Diagnostic and Statistical Manual) DSM-IV criteria
- Non-treatment seeking
Exclusion Criteria:
- Female participants who are currently pregnant or breastfeeding. Lack of effective birth control 10 days before Study Day 1 (15 days prior to the first PET scan)
- Self-reported use of methadone, buprenorphine, or levo-alpha-acetylmethadol (LAAM) in the past 14 days
- Participants who have a positive history of neurological illness (including epilepsy) or those who have received anti-convulsant therapy during the past 5 years
- Liver disease requiring medication or medical treatment, and/or aspartate or alanine aminotransferase levels greater than 3 times the upper limit of normal
- Gastrointestinal or renal disease that would significantly impair absorption, metabolism or excretion of study drug, or require medication or medical treatment
- Neurological or psychiatric disorders including psychosis, bipolar disorder, organic brain disease, any seizure history or other disorders that require treatment or that could make study compliance difficult
- Positive tuberculosis (PPD) TB skin test along with a clinical history and chest X-ray indicative of active tuberculosis. (Individuals who have a positive PPD test and have a negative chest X-ray, are not symptomatic for tuberculosis, and do not require anti-tuberculosis therapy will be eligible to participate. Participants will be asked if they ever tested positive for tuberculosis. If so, they will not be given a PPD and a chest X-ray and clinical history will be used for evaluation purposes).
- Presence or positive history of severe medical illness or any cardiovascular disease or heart abnormality, such as low hemoglobin (Hb < 13 g/dL in males, Hb < 11 g/dL in females), or BP > 150/90.
- Requirement for any of the following medications (current or within the past 4 weeks): psychotropics (including sedative/hypnotics, antidepressants, neuroleptics), anticonvulsants, antihypertensives, antiarrhythmics, or antiretroviral medications,. Participants on any current psychoactive prescription medications will be excluded.
- Current dependence (by DSM-IV criteria) on methadone, LAAM, or buprenorphine
- Participants for whom detoxification is not "clinically recommended" such as those with a significant history of overdose following detoxification
- Participation in an investigational drug study within the past 3 months
- Hypersensitivity to any of the medications used in this study
- Participants who are positive for HIV or chronic active hepatitis
- Metal implants or paramagnetic objects contained within the body which may interfere with the MRI scan, as determined in consultation with a neuroradiologist and according to the guidelines set forth in the following reference book commonly used by neuroradiologists: "Guide to MR procedures and metallic objects" Shellock Frank G., Lippincott Williams & Wilkins Healthcare, Philadelphia, 2001.
- Lifetime exposure to radiation in the workplace, or participation in nuclear medicine procedures, including research protocols, in the past year
- Positive Allen Test indicating lack of collateral blood flow to hand
- History of Reynaud's syndrome
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo
This group will receive placebo drug
|
Placebo drug will be administered orally twice a day (BID) for two consecutive weeks
Other Names:
|
Experimental: Low-dose AV411
This group will receive a low dose of AV411
|
Low (20 mg), and high dose (40 mg) of AV411 will be administered orally twice a day (BID) for two consecutive weeks
Other Names:
|
Experimental: High-dose AV411
This group will receive a high dose of AV411
|
Low (20 mg), and high dose (40 mg) of AV411 will be administered orally twice a day (BID) for two consecutive weeks
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Subjective Opioid Withdrawal Scale Score (SOWS)
Time Frame: Measured at the end of each two-week maintenance period (i.e., Placebo, Low AV411, High AV411).
|
Measures severity of opioid withdrawal in opioid dependent populations (0-64).
Larger values indicate more severe withdrawal.
|
Measured at the end of each two-week maintenance period (i.e., Placebo, Low AV411, High AV411).
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The Effects of AV411 on the Analgesic Effects of Oxycodone.
Time Frame: Measured at the end of each AV411 of the three two-week maintenance periods
|
The McGill Pain Questionnaire (Melzack, 1987) was used to assess pain experience immediately following the immersion of the hand in 4 degree Celsius water.
Scores were added across all 15 items to generate a sum score, which ranged between 15 and 60.
Larger scores indicate greater pain levels.
|
Measured at the end of each AV411 of the three two-week maintenance periods
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Investigators
- Principal Investigator: Sandra D Comer, PhD, New York State Psychiatric Institute and Columbia University
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Cooper ZD, Johnson KW, Pavlicova M, Glass A, Vosburg SK, Sullivan MA, Manubay JM, Martinez DM, Jones JD, Saccone PA, Comer SD. The effects of ibudilast, a glial activation inhibitor, on opioid withdrawal symptoms in opioid-dependent volunteers. Addict Biol. 2016 Jul;21(4):895-903. doi: 10.1111/adb.12261. Epub 2015 May 14.
- Jacobsen JH, Watkins LR, Hutchinson MR. Discovery of a novel site of opioid action at the innate immune pattern-recognition receptor TLR4 and its role in addiction. Int Rev Neurobiol. 2014;118:129-63. doi: 10.1016/B978-0-12-801284-0.00006-3.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
October 1, 2008
Primary Completion (Actual)
April 1, 2010
Study Completion (Actual)
June 1, 2012
Study Registration Dates
First Submitted
July 24, 2008
First Submitted That Met QC Criteria
July 24, 2008
First Posted (Estimate)
July 28, 2008
Study Record Updates
Last Update Posted (Estimate)
December 5, 2016
Last Update Submitted That Met QC Criteria
October 11, 2016
Last Verified
October 1, 2016
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Mental Disorders
- Chemically-Induced Disorders
- Substance-Related Disorders
- Narcotic-Related Disorders
- Opioid-Related Disorders
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Vasodilator Agents
- Autonomic Agents
- Peripheral Nervous System Agents
- Enzyme Inhibitors
- Platelet Aggregation Inhibitors
- Bronchodilator Agents
- Anti-Asthmatic Agents
- Respiratory System Agents
- Phosphodiesterase Inhibitors
- Ibudilast
Other Study ID Numbers
- #5725
- P50DA009236 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Yes
IPD Plan Description
Data have been published in a peer-reviewed journal.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Opioid-Related Disorders
-
Bicycle HealthEnrolling by invitationOpioid Use Disorder | Opioid Dependence | Opioid Use | Opioid Abuse | Opioid MisuseUnited States
-
Baylor College of MedicineChandrakantanWithdrawnOpioid Dependence | Opioid Use | Opioid Abuse, Unspecified
-
University of ArkansasNational Institute on Drug Abuse (NIDA)CompletedOpioid Dependence | Opioid Withdrawal | Opioid DetoxificationUnited States
-
MindLight, LLCHarvard Medical School (HMS and HSDM); National Institute on Drug Abuse (NIDA) and other collaboratorsCompletedOpioid Dependence | Opioid Abuse | Opioid-use DisorderUnited States
-
New York State Psychiatric InstituteColumbia University; Weill Medical College of Cornell University; National Institute... and other collaboratorsActive, not recruitingOpioid Use | Opioid Court Model | Medication to Treat Opioid Use DisorderUnited States
-
Vanderbilt University Medical CenterCompletedOpioid Use | Opioid-use DisorderUnited States
-
University of PennsylvaniaCompletedSurgery | Opioid Use | Opioid Misuse | Prescription Opioid MisuseUnited States
-
University of MinnesotaRecruitingOpioid Dependence | Opioid Abuse | Opioid-use DisorderUnited States
-
Brigham and Women's HospitalOhio State UniversityActive, not recruitingOpioid Dependence | Opioid Use | Opioid-use DisorderUnited States
-
MindLight, LLCMclean HospitalRecruitingOpioid Dependence | Opioid Use | Opioid Abuse | Opiate Dependence | Opioid Use, Unspecified | Opioid Use Disorder, ModerateUnited States
Clinical Trials on Placebo (PCB)
-
Clinical Nutrition Research Center, Illinois Institute...Ingredion IncorporatedCompleted
-
National Institute of Allergy and Infectious Diseases...Mexican Emerging Infectious Diseases Clinical Research NetworkCompletedSevere Acute Respiratory IllnessMexico
-
University of California, San DiegoCompletedPain Due to Intrauterine Contraceptive DeviceUnited States
-
Deutsches Herzzentrum MuenchenCompleted
-
InnoRa GmbHCompletedCoronary Artery DiseaseMalaysia
-
Universitat Internacional de CatalunyaDentaid SLCompletedDental Plaque | Side EffectsSpain
-
Ciusss de L'Est de l'Île de MontréalWithdrawnShoulder Surgery | Regional Anesthesia MorbidityCanada
-
Udayana UniversityRecruitingLower Extremity SurgeryIndonesia
-
Hospital de Clinicas de Porto AlegreCompletedDepression | Pain | Sleep Disorders, Circadian Rhythm | Genotoxicity
-
InnoRa GmbHCompletedCoronary Artery DiseaseSwitzerland, Germany